Recombinant Human-Activated Protein C (rhAPC) in Childhood Sepsis

1. Rawicz M, Sitkowska B, Rudzinska I, Kornacka KM, Bochenski P. Recombinant human activated protein C for severe sepsis in a neonate . Med Sci Monit. 2002;8(11): CS90-CS94 .

2. Xigris® (drotrecogen alfa-activated) [package insert]. Indianapolis, IN: Eli Lilly and Company ; November 2001.

3. Bernard GR, Ely EW, Wright TJ, et al. Safety and dose- relationship of recombinant human activated protein C (rhAPC) on coagulopathy in severe sepsis . N Engl J Med. 2001;344: 699-709 .

4. FDA Anti-Infective Drug Advisory Committee. Briefing Document for Xigris® for the Treatment of Severe Sepsis. Eli Lilly. Retrieved September 12, 2001, from http://www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_01_Sponsor.pdf

5. Giroir B. Recombinant human activated protein C for the treatment of severe sepsis: is there a role in pediatrics? Curr Opin Pediatr. 2003;15: 92-96 .

6. U.S. Food and Drug Administration. FDA Clinical Review Drotrecogen alfa (activated) [Recombinant Human Activated Protein C [rhAPC] Xigris® BLA# 125029/0. Approved November 21, 2001. http://www.fda.gov/cber/review/droteli112101r1.htm

7. Yan SB, Helterbrand JD, Hartman DL, et al. Low levels of protein C are associated with poor outcome in severe sepsis . Chest. 2001;120: 915-922 .

8. DeKleijn ED, Hazelet JA, Komelisse RF, et al. Pathophysiology of meningococcal sepsis in children . Eur J Pediatr. 1998;157: 869-880 .

9. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care . Crit Care Med. 2001;29(7): 1303-1310 .

10. Kutco MC, Calarco MP, Flaherty MB, et al. Mortality rates in pediatric septic shock with and without multiple organ system failure . Pediatr Crit Care Med. 2003;4(3): 333-337 .